Results 31 to 40 of about 105,114 (279)

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer [PDF]

, 2006
Background Anti-angiogenic treatment is believed to have at least cystostatic effects in highly vascularized tumours like pancreatic cancer. In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were compared with
Castellano Daniel, Kleeff Jörg, Vermorken Jan, Albert Abad Esteve, Simon van Belle, CASTELLANO, D, STOGER, H, Esteve, Albert Abad, Jochen Raedle, HERZOG, P, DAVIDSON, N, OETTLE, H, Balcke, Peter, SCHEITHAUER, W, DOBROWOLSKI, F, TEMPIA-CALIERA, AA, Neville Davidson, Langrehr, Jan M., Herzog Peter, Scheithauer Werner, Friess Helmut, HOSSFELD, DK, KOVAR, A, Herbert Stöger, Adrien A Tempia-Caliera, Jan M Langrehr, Neyns Bart, Bart Neyns, Castellano, Daniel, Oettle Helmut, Herzog, Peter, BALCKE, P, Dittrich, Christian, KATZ, F, Katz Frieder, Robert Hawkins, Hawkins Robert, Raedle, Jochen, PIEDBOIS, P, LANGREHR, JM, Pascal Piedbois, Werner Scheithauer, Dobrowolski, Frank, NIEDERGETHMANN, M, Nippgen Johannes, Hawkins, Robert, Van Belle, Simon, Piedbois Pascal, Raedle Jochen, Andreas Kovar, RAEDLE, J, HAWKINS, R, Stöger Herbert, Peter Balcke, Davidson, Neville, Tempia-Caliera, Adrien A., DITTRICH, C, Christian Dittrich, Hossfeld Dieter K, Tempia-Caliera Adrien A, Helmut Oettle, NIPPGEN, J, Esteve Albert, ESTEVE, AA, Balcke Peter, Friess, Helmut, Katz, Frieder, Oettle, Helmut, Hossfeld, Dieter K., Dobrowolski Frank, Peter Herzog, Daniel Castellano, Kleeff, Jörg, Niedergethmann Marco, Marco Niedergethmann, Dieter K Hossfeld, Jan Vermorken, Scheithauer, Werner, KLEEFF, J, Helmut Friess, Nippgen, Johannes, NEYNS, B, Jörg Kleeff, Dittrich Christian, Langrehr Jan M, Davidson Neville, Stöger, Herbert, Frank Dobrowolski, Frieder Katz, Kovar, Andreas, Johannes Nippgen, van Belle Simon, Niedergethmann, Marco, Vermorken, Jan, Kovar Andreas, FRIESS, H, Piedbois, Pascal, Neyns, Bart, VERMORKEN, J, Stoeger, Herbert, [et al.]   +100 more
core   +2 more sources

Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? [PDF]

, 2003
Background: Serial kinetics of serum CA 19-9 levels have been reported to reflect response and survival in patients with pancreatic cancer undergoing surgery, radiotherapy, and chemotherapy.
Stoffregen, C., Stemmler, J., Wilkowski, R., Garbrecht, M., Schalhorn, A., Lamerz, Rolf, Stieber, P., Szymala, A. M., Schermuly, M. M., Heinemann, Volker, Helmberger, T., Niebler, K.   +11 more
core   +1 more source

Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer [PDF]

, 2007
Objective: To date, no standard regimen for salvage chemotherapy after gemcitabine (Gem) failure has been defined for patients with advanced pancreatic cancer (PC). Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in
Haas, Michael, Haas, M., Wilkowski, R., Schulz, Christoph, Moosmann, Nicolas, Heinemann, V., Golf, Alexander, Bruns, Christiane J., Laessig, Dorit, Golf, A., Heinemann, Volker, Boeck, S., Moosmann, N., Issels, Rolf-Dieter, Wilkowski, Ralf, Laessig, D., Issels, R.D., Boeck, Stefan, Bruns, C.J., Schulz, C.   +19 more
core   +1 more source

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group [PDF]

, 2005
Purpose: This phase III randomized trial compared two chemotherapy regimens, gemcitabine plus carboplatin and mitomycin, ifosfamide, and cisplatin, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC).
Harper, P.G., Johnson, P.W.M., Harper, P. G., Qian, W., Rudd, R. M., Spiro, S.G., Gregory, W. M., Hatton, M., Eisen, T. G., James, L.E., Rankin, E. M., Johnson, P. W. M., Rankin, E.M., Spiro, S. G., Rudd, R.M., Lee, S. M., Littler, J. A. H., Lee, S.M., Littler, J.A.H., Eisen, T.G., Martin, W.M.C., Gregory, W.M., James, L. E., Gower, N. H., Martin, W. M. C., Gower, N.H.   +25 more
core   +1 more source

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma

Journal of Hematology & Oncology, 2011
Background The objectives of the present study are to investigate the efficacy and safety profile of gemcitabine-based combinations in the treatment of locally advanced and metastatic pancreatic adenocarcinoma (LA/MPC).
Ma Yue, Xu Ying-Chun, Tang Lei, Wang Hong-Xia, Zhao Gang, Hu Jing, Zhang Feng-Chun   +6 more
doaj   +1 more source

Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: Pretreatment levels or kinetics during chemotherapy? [PDF]

, 2007
Background: The carbohydrate antigen 19-9 (CA 19-9) is currently the most widely used serum tumor marker in pancreatic cancer (PC). CA 19-9 pretreatment levels as well as CA 19-9 kinetics during systemic chemotherapy can provide prognostic information ...
Holdenrieder, Stefan, Weckbach, Sabine, Schulz, Christoph, Boeck, Stefan, Heinemann, Volker, Stieber, Petra   +5 more
core   +1 more source

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Naomi Walsh, Martin Clynes, Rizwan Sheikh, Sheikh, Rizwan, O'Connor, Robert A., Robert O’Connor, Ray McDermott, O'Connor, Robert, Clynes, Martin, Walsh, Naomi, McDermott, Ray   +10 more
core   +1 more source

Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia. [PDF]

, 2011
Irinotecan-containing regimens are known to be active and tolerable in patients with non-small cell lung cancer (NSCLC). A randomized phase II trial was conducted to evaluate the efficacy of irinotecan plus paclitaxel or gemcitabine for previously ...
Akitoshi Kinoshita, Kasai, Takashi, Nagashima, Seiji, Soejima, Yoshifumi, Yoshifumi Soejima, Tsukamoto, Kazuhiro, Fukuda, Minoru, Katsumi Nakatomi, Takatani, Hiroshi, Shigeru Kohno, Minoru Fukuda, Seiji Nagashima, Fukuda, Masaaki, Kazuhiro Tsukamoto, Yoichi Nakamura, Mikio Oka, Masuda, Noriyuki, Nakamura, Yoichi, Hiroshi Soda, Hiroshi Takatani, Oka, Mikio, Nakatomi, Katsumi, Masaaki Fukuda, Noriyuki Masuda, Kohno, Shigeru, Kinoshita, Akitoshi, Soda, Hiroshi, Takashi Kasai   +27 more
core   +1 more source

Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma

Cancer Biology & Medicine, 2023
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%. Of PDAC patients, 15%-20% are eligible for radical surgery.
Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yang Liu, Xiaoqing Ma, Jinsheng Ding, Shengyu Yang, Ran Zhao, Antao Chang, Chuntao Gao, Jing Liu, Tiansuo Zhao, Xiuchao Wang, Chongbiao Huang, Song Gao, Ying Ma, Bo Tang, Yukuan Feng, Hongwei Wang, Jihui Hao   +19 more
doaj   +1 more source

Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway

Redox Biology, 2019
Chemoresistance is a major therapeutic obstacle in the treatment of human pancreatic ductal adenocarcinoma (PDAC). As an oxidative stress responsive transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2) regulates the expression of ...
Yunjiang Zhou, Yang Zhou, Mengdi Yang, Keke Wang, Yisi Liu, Mingda Zhang, Yunjia Yang, Chenyu Jin, Rui Wang, Rong Hu   +9 more
doaj   +1 more source